Affinity Asset Advisors, LLC Global Blood Therapeutics, Inc. Transaction History

Affinity Asset Advisors, LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	BUY	$32.4 - $68.18 $6.16 Million - $13 Million	190,000 New	190,000 $12.9 Million
Q2 2022 Aug 12, 2022	SELL	$22.3 - $37.39 $1.56 Million - $2.62 Million	-70,000 Closed	0 $0
Q1 2022 May 13, 2022	BUY	$25.68 - $35.59 $1.8 Million - $2.49 Million	70,000 New	70,000 $2.43 Million
Q4 2021 Feb 11, 2022	SELL	$24.9 - $40.26 $1.87 Million - $3.02 Million	-75,000 Closed	0 $0
Q3 2021 Nov 12, 2021	BUY	$25.48 - $37.34 $1.4 Million - $2.05 Million	55,000 Added 275.0%	75,000 $1.91 Million
Q1 2021 May 14, 2021	SELL	$38.94 - $50.85 $1.17 Million - $1.53 Million	-30,000 Reduced 60.0%	20,000 $815,000
Q4 2020 Feb 12, 2021	BUY	$37.65 - $63.77 $1.88 Million - $3.19 Million	50,000 New	50,000 $2.17 Million

288K

Ticker GBT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 67,476,200
Market Cap $4.62B
Description
Global Blood Therapeutics, Inc., a biopharmaceutical company, engages in the discovery, development, and delivery of treatments for underserved patient communities with sickle cell disease (SCD). The company offers Oxbryta tablets, an oral, once-daily therapy for SCD. It also evaluates the safety and pharmacokinetics of single and multiple doses...

Get notified when there are updates to the investment portfolio of Affinity Asset Advisors, LLC, based on Form 13F filings with the SEC.

Stay updated on Affinity Asset Advisors, LLC with notifications on news.